News
Menstrual health apps market tipped to reach US$13bn

The global menstrual health apps market is forecast to reach US$13.11bn by 2035, up from US$2.07bn in 2025, according to a new industry report.
The analysis estimates the menstrual health apps sector will grow at a compound annual growth rate of 20.28 per cent, driven by rising awareness of reproductive health, wider smartphone use and demand for personalised health tracking.
North America accounted for the largest share of the market in 2024, supported by high smartphone penetration, strong reproductive health awareness and early adoption of digital health tools.
The Asia Pacific region is expected to grow at the fastest rate, driven by a large reproductive-age population and increasing access to affordable digital health services.
Period tracking apps led the market in 2025.
Faster growth is expected in apps focused on managing menstrual disorders such as polycystic ovary syndrome, a hormonal condition that can cause irregular periods, and premenstrual dysphoric disorder, a severe form of premenstrual syndrome.
Android held the dominant platform position in 2025 due to its large global user base, particularly in emerging markets. iOS is expected to grow at the fastest rate, driven by demand for advanced features and compatibility with wearable devices.
The report highlights challenges facing the sector, including data privacy and security concerns around sensitive health information, limited digital literacy in developing regions, cultural stigma around menstruation and inconsistent accuracy of cycle predictions.
Recent developments include period tracking app Comma raising US$2m in seed funding in March 2025.
In January 2025, Nigerian non-profit Big Family 360 Foundation launched HerPride, an app that enables women to track cycles and access sanitary products.
In November 2024, Flo Health partnered with FemTech India to expand access to menstrual health education through complimentary premium subscriptions.
Healthcare providers and integrated platforms are expected to be the fastest-growing distribution channel, as collaboration increases between app developers and hospitals, clinics and telehealth services.
Menopause
Apple Health adds menopause and perimenopause tracking

Apple announced menopause and perimenopause tracking for its Health app at WWDC 2026, with symptom logging and cycle alerts for some users.
The update expands the app’s cycle tracking beyond fertility and menstrual periods.
If logged cycle patterns suggest a user may be experiencing perimenopause, the app will send a notification prompting a conversation with a doctor.
However, this perimenopause-specific cycle deviation notification is only for users aged 40 and over and is not intended to replace a doctor’s diagnosis or treatment.
Stacey Ford, Apple’s vice-president of OS management, said users will also be able to log menopause and perimenopause symptoms in the Health app.
Educational content will also be available to help users learn more about these life stages and understand changes in their bodies.
Every year, about 2 million women enter perimenopause, the stage before menopause when levels of the hormone oestrogen decline.
According to a February 2025 survey involving 4,432 participants aged over 30, more than half of women aged 30 to 35 experienced moderate or severe perimenopause symptoms.
The findings suggest perimenopause does not affect only older adults.
About 6,000 women in the US enter menopause every day, according to the Society for Women’s Health Research.
Given the number of women affected by perimenopause and menopause, the update broadens the Health app’s scope.
The app launched in 2019, meaning it has gone seven years without these women’s health tracking features, which could help users better understand their bodies and prepare for informed conversations with doctors.
Mental health
£50m initiative aims to tackle disparities in maternal healthcare
Insight
Peers call on UK government to review fertility and surrogacy laws

Peers have called for law reform after two House of Lords debates on fertility treatment, surrogacy, embryo research and declining birthrates.
The first debate was put forward by crossbench peer Baroness Ruth Deech, who previously chaired the UK’s fertility regulator, the Human Fertilisation and Embryology Authority.
She discussed proposals from the HFEA to reform the Human Fertilisation and Embryology Act, along with proposals from the Scottish Law Commission and the Law Commission of England and Wales to reform the Surrogacy Arrangements Act.
She called for parliamentary scrutiny of possible changes to regulatory powers, consent rules, donor information and future scientific developments.
Baroness Deech said: “Parliament should plan by setting up a Select Committee to examine the HFEA’s proposals to expand regulatory powers, simplify consent rules, modernise donor information provisions and create a flexible framework for future scientific developments.”
Former fertility professionals were among those contributing to the debate.
Professor Lord Robert Winston, a Labour peer who founded the IVF service at Hammersmith Hospital in London, said: “Infertility is not a disease; it is actually a symptom of something wrong.”
Professor Baroness Geeta Nargund, a Labour peer, current HFEA member and former medical director of CREATE Fertility, disagreed.
She said: “Infertility is a disease, as stated by the World Health Organisation.”
Liberal Democrat peer Baroness Caroline Pidgeon highlighted regional differences in access to NHS-funded fertility treatment.
She cited figures from the Progress Educational Trust’s NHS Fertility Funding Tracker showing that only two of England’s 42 integrated care boards comply with the recently updated fertility guideline published by the National Institute for Health and Care Excellence.
Integrated care boards are local NHS organisations responsible for planning and funding healthcare services in their areas.
Baroness Pidgeon said many boards were offering only a partial IVF cycle rather than a full cycle as defined by NICE.
A full IVF cycle generally includes ovarian stimulation, egg collection and the transfer of all suitable fresh and frozen embryos created during treatment.
Crossbench peer Professor Baroness Clare Gerada, a former president of the Royal College of General Practitioners, said: “The proportion of NHS-funded IVF cycles has fallen to just under 30 per cent, the lowest level since 2008.”
She added that, in relation to IVF, “the NHS system has collapsed”.
Liberal Democrat peer Lord Monroe Palmer said it was “very ironic that it is difficult for many patients to access publicly funded fertility treatment in the very country where IVF was originally pioneered”.
Conservative peer Edward Howard, Earl of Effingham, also raised concerns about the NICE fertility guideline.
He said: “Access remains highly variable across England, because ICBs are not required to implement that guidance.”
He described the situation as “a clear gap between guidance and enforceable entitlement”.
Baroness Deech called for “automatic record sharing between clinics and the NHS central records system”.
Baroness Nargund supported this and linked the ambition to the Single Patient Record in the government’s Ten-Year Health Plan for England and the Health Bill currently before Parliament.
Baroness Pidgeon said such ambitions were at odds with the exceptional degree of medical secrecy that currently applies to IVF.
She also pointed to “a clear desire for the HFEA to be able to permit patients to give generic consent for the use of their embryos in research”.
Patients cannot currently give broad consent for unspecified future research involving their embryos.
Responding for the government, Labour peer Baroness Judith Blake said “immediate legislative reform” was not possible because “the legislative programme for this Parliamentary session is very full”.
Baroness Deech replied: “It might well take some years, but the Government really needs to set up that Select Committee and do the legislative scrutiny right now.”
A second debate on related issues followed immediately afterwards.
Baroness Nargund asked the government “what assessment they have made of the UK’s declining birthrates in an ageing population”.
She also said: “We still have a postcode lottery for IVF provision, with nearly 70 per cent of ICBs funding only one cycle of treatment.”
Responding for the government, Labour peer Lord Philip Wilson said: “The Government are committed to improving fair and equitable access to fertility services, recognising the significant emotional and health impacts of infertility.”
Menopause2 weeks agoPerimenopause misinformation ‘putting women at risk’
Hormonal health3 weeks agoNHS urged to update website following renaming of PCOS
Hormonal health4 weeks agoPCOS renamed after decade-long campaign to end ‘cyst’ misconception
News2 weeks agoWomen still being failed when they reach menopause, experts say
Entrepreneur2 weeks agoWomen’s Health Innovation Summit opens submissions for 2026 Innovation Showcase
Diagnosis4 weeks agoArtera receives FDA Clearance for breast cancer platform
Fertility4 weeks agoAI could transform ovarian care through personalisation, study finds
News2 weeks agoThree menopause innovators shortlisted for Femtech World Award
















Pingback: doxycycline for sinus infection
Pingback: cialis 5mg uses
Pingback: sildenafil 100mg indications
Pingback: sémaglutide injection prix new jersey
Pingback: innehåller mounjaro semaglutid
Pingback: doxycycline work for sinus infection
Pingback: doxycycline hyclate 100 mg tablet
Pingback: metronidazole gel 1.5 w/w price
Pingback: bupropion alternative names
Pingback: cost liraglutide
Pingback: xenical cost ireland